Drug intelligence / Profile preview

Gu'anzhu

Development stage: Unknown
Lead developer: Kitanihon Pharmaceutical
Administration: Oral

Overview

Gu'anzhu (固安殊) is a traditional herbal medicine formulation developed by Kitanihon Pharmaceutical in collaboration with the Jiusheng Yuan TCM Research Institute Beijing. It is designed to treat degenerative bone diseases, including osteoarthritis and osteoporosis. The formulation is a botanical extract derived from traditional Chinese and Japanese medicine principles, utilizing AI-based herb evaluation technology developed by the team of Academician Cheng Jing. Originally developed as a powder (13g/dose), it has been upgraded to a tablet form (1.2g/dose) for improved patient compliance. In Japan, it is classified as a functional food (機能性表示食品). Clinical development includes a completed Phase 1 randomized controlled trial and an ongoing large-scale real-world study targeting 1,500 cases.

Brand names: 固安殊Gu'anzhu

Beyond the preview

Go deeper on Gu'anzhu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gu'anzhu.

Explore the full profile